Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial
Makito Miyake · 2025
Read Impact of durable response of first-line systemic treatment for patients with locally advanced or metastatic urothelial carcinoma: data update of EV-302/KEYNOTE-A39 trial by Makito Miyake (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12779424.txt.
Description
Makito Miyake wrote a 2025 update on a trial of first treatment for bladder and urinary tract cancer that had spread. The cancer starts in the lining of the bladder, ureter, or kidney outlet. Once it spreads, patients have often lived less than two years on standard drug care.
The update covers a large trial, known as EV-302 or KEYNOTE-A39, that paired two newer drugs as the first treatment. The focus is on patients whose response to care lasted a long time. The report asks what a lasting response means for how long patients live and how they fare over time. Such updates help doctors judge whether a strong early response can turn into years of control, and they guide talks with patients about what to expect from care.
Catalog record
| CREATOR | Makito Miyake |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |